Pennsylvania sues insulin makers and PBMs for alleged price‑fixing scheme
The Pennsylvania Attorney General filed a lawsuit against 17 pharmaceutical companies and pharmacy‑benefit managers, including Eli Lilly, Sanofi, Novo Nordisk, CVS Caremark and OptumRx. The complaint alleges the defendants colluded to raise insulin prices by more than 1,000% since the mid‑2000s, harming about 1.3 million diabetics in the state. The state seeks restitution for patients, injunctive relief and civil penalties under its consumer‑protection law.
Why it matters
If the court rules for Pennsylvania, the companies could face civil penalties of $1,000 per violation and $3,000 per violation involving seniors, plus restitution payments, which may affect earnings and cash flow. The lawsuit also raises reputational risk and could prompt further regulatory scrutiny of insulin pricing.
Key facts
- 1The lawsuit names 17 pharma companies and PBMs, including Eli Lilly, Sanofi, Novo Nordisk, CVS Caremark and OptumRx. phillyvoice.com
- 2The suit alleges the price‑inflation scheme affected 1.3 million Pennsylvania residents with diabetes. phillyvoice.com
- 3It also cites 3.5 million residents with prediabetes as being impacted. phillyvoice.com
- 4Insulin prices were allegedly raised from about $20 to a range of $300 to $700 per prescription. phillyvoice.com
- 5Civil penalties sought are $1,000 for each violation of the Unfair Trade Practices and Consumer Protection Law. phillyvoice.com
- 6For violations involving victims 60 years or older, the penalty is $3,000 per violation. phillyvoice.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.